611 related articles for article (PubMed ID: 35814522)
1. Overview of Complications in Cirrhosis.
Premkumar M; Anand AC
J Clin Exp Hepatol; 2022; 12(4):1150-1174. PubMed ID: 35814522
[TBL] [Abstract][Full Text] [Related]
2. Natural History of Cirrhosis of Liver after First Decompensation: A Prospective Study in India.
Shah AS; Amarapurkar DN
J Clin Exp Hepatol; 2018 Mar; 8(1):50-57. PubMed ID: 29743797
[TBL] [Abstract][Full Text] [Related]
3. Where does TIPS fit in the management of patients with cirrhosis?
García-Pagán JC; Saffo S; Mandorfer M; Garcia-Tsao G
JHEP Rep; 2020 Aug; 2(4):100122. PubMed ID: 32671331
[TBL] [Abstract][Full Text] [Related]
4. Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event.
Balcar L; Tonon M; Semmler G; Calvino V; Hartl L; Incicco S; Jachs M; Bauer D; Hofer BS; Gambino CG; Accetta A; Brocca A; Trauner M; Mandorfer M; Piano S; Reiberger T;
JHEP Rep; 2022 Aug; 4(8):100513. PubMed ID: 35845294
[TBL] [Abstract][Full Text] [Related]
5. The portal hypertension syndrome: etiology, classification, relevance, and animal models.
Bosch J; Iwakiri Y
Hepatol Int; 2018 Feb; 12(Suppl 1):1-10. PubMed ID: 29064029
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis and Management of Cirrhotic Cardiomyopathy.
Kaur H; Premkumar M
J Clin Exp Hepatol; 2022; 12(1):186-199. PubMed ID: 35068798
[TBL] [Abstract][Full Text] [Related]
7. Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.
Frenette C; Kayali Z; Mena E; Mantry PS; Lucas KJ; Neff G; Rodriguez M; Thuluvath PJ; Weinberg E; Bhandari BR; Robinson J; Wedick N; Chan JL; Hagerty DT; Kowdley KV;
J Hepatol; 2021 Feb; 74(2):274-282. PubMed ID: 33038432
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of Portal Pressure-Guided Therapy in Decompensated Cirrhosis With Index Variceal Bleed in Asian Cohort.
Sharma S; Agarwal S; Gunjan D; Kaushal K; Anand A; Gopi S; Mohta S; Saraya A
J Clin Exp Hepatol; 2021; 11(4):443-452. PubMed ID: 34276151
[TBL] [Abstract][Full Text] [Related]
9. Presentation and complications associated with cirrhosis of the liver.
Poordad FF
Curr Med Res Opin; 2015 May; 31(5):925-37. PubMed ID: 25697811
[TBL] [Abstract][Full Text] [Related]
10. Clinical features and predictors of outcome in acute hepatitis A and hepatitis E virus hepatitis on cirrhosis.
Radha Krishna Y; Saraswat VA; Das K; Himanshu G; Yachha SK; Aggarwal R; Choudhuri G
Liver Int; 2009 Mar; 29(3):392-8. PubMed ID: 19267864
[TBL] [Abstract][Full Text] [Related]
11. Long-term Outcomes with Carvedilol versus Propranolol in Patients with Index Variceal Bleed: 6-year Follow-up Study.
Sharma S; Agarwal S; Gunjan D; Kaushal K; Anand A; Mohta S; Shalimar ; Saraya A
J Clin Exp Hepatol; 2021; 11(3):343-353. PubMed ID: 33994717
[TBL] [Abstract][Full Text] [Related]
12. Current Medical Treatment for Alcohol-Associated Liver Disease.
Ayares G; Idalsoaga F; Díaz LA; Arnold J; Arab JP
J Clin Exp Hepatol; 2022; 12(5):1333-1348. PubMed ID: 36157148
[TBL] [Abstract][Full Text] [Related]
13. Impact of etiological treatment on prognosis.
Su CW; Yang YY; Lin HC
Hepatol Int; 2018 Feb; 12(Suppl 1):56-67. PubMed ID: 28702738
[TBL] [Abstract][Full Text] [Related]
14. Dietary cholesterol intake is associated with progression of liver disease in patients with chronic hepatitis C: analysis of the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis trial.
Yu L; Morishima C; Ioannou GN
Clin Gastroenterol Hepatol; 2013 Dec; 11(12):1661-6.e1-3. PubMed ID: 23707779
[TBL] [Abstract][Full Text] [Related]
15. Recompensation in Cirrhosis: Current Evidence and Future Directions.
Sharma S; Roy A
J Clin Exp Hepatol; 2023; 13(2):329-334. PubMed ID: 36950490
[TBL] [Abstract][Full Text] [Related]
16. Surgical Risk Assessment in Patients with Chronic Liver Diseases.
Jadaun SS; Saigal S
J Clin Exp Hepatol; 2022; 12(4):1175-1183. PubMed ID: 35814505
[TBL] [Abstract][Full Text] [Related]
17. The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes.
Younossi Z; Aggarwal P; Shrestha I; Fernandes J; Johansen P; Augusto M; Nair S
JHEP Rep; 2022 Sep; 4(9):100525. PubMed ID: 36039144
[TBL] [Abstract][Full Text] [Related]
18. Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response.
Shen Y; Wu SD; Chen Y; Li XY; Zhu Q; Nakayama K; Zhang WQ; Weng CZ; Zhang J; Wang HK; Wu J; Jiang W
Gut Microbes; 2023; 15(1):2155018. PubMed ID: 36519342
[TBL] [Abstract][Full Text] [Related]
19. Management of Portal Hypertension.
Kulkarni AV; Rabiee A; Mohanty A
J Clin Exp Hepatol; 2022; 12(4):1184-1199. PubMed ID: 35814519
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension.
Lens S; Baiges A; Alvarado-Tapias E; LLop E; Martinez J; Fortea JI; Ibáñez-Samaniego L; Mariño Z; Rodríguez-Tajes S; Gallego A; Bañares R; Puente Á; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; García-Pagán JC; Forns X
J Hepatol; 2020 Dec; 73(6):1415-1424. PubMed ID: 32535060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
